Table 1. Clinical Characteristics of Study Samples.
| GWAS | Replication | Validation | ||||||||
| T2DM Case-Control | IRAS | IRASFS | ||||||||
| T2DM-ESRD | Control | T2DM-ESRD | Control | T2DM | Control | T2DM | Control | T2DM | Control | |
| n | 965 | 1029 | 709 | 690 | 1246 | 927 | 115 | 164 | 97 | 507 |
| Female (%) | 61.2% | 57.3% | 55.7% | 51.3% | 64.0% | 58.0% | 53.9% | 61.0% | 70.1% | 58.0% |
| Age at Enrollment (years) | 61.6±10.5 | 49.0±11.9 | 60.2±10.4 | 48.5±12.8 | 57.2±11.7 | 46.6±13.1 | 56.8±8.0 | 54.5±8.4 | 53.9±11.2 | 40.8±13.5 |
| Age at T2DM diagnosis (years) | 41.6±12.4 | ― | 39.4±12.5 | ― | 46.1±12.6 | 51.1±10.7 | ― | 51.2±11.9 | ― | |
| Age at ESRD diagnosis (years) | 58.0±10.9 | ― | 56.7±10.9 | ― | ― | ― | ― | ― | ― | ― |
| T2DM to ESRD duration (years) | 16.2±10.9 | ― | 20.4±10.5 | ― | ― | ― | ― | ― | ― | ― |
| BMI (kg/m2) | 29.7±7.0 | 30.0±7.0 | 29.8±6.9 | 29.4±7.6 | 33.5±7.6 | 30.0±7.7 | 32.1±6.0 | 29.3±5.8 | 34.1±6.8 | 29.2±6.5 |
Values are presented as trait mean and standard deviation.